Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation (CROSBI ID 642031)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Radić Antolic, Margareta ; Horvat, Ivana ; Serventi Seiwerth, Ranka ; Vrhovac, Radovan ; Sertic, Dubravka ; Nemet, Damir ; Zadro, Renata Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation. 2015

Podaci o odgovornosti

Radić Antolic, Margareta ; Horvat, Ivana ; Serventi Seiwerth, Ranka ; Vrhovac, Radovan ; Sertic, Dubravka ; Nemet, Damir ; Zadro, Renata

engleski

Quantitative assessment of minimal residual disease in cytogenetically normal AML carrying NPM1 mutation A with or without FLT3-ITD mutation

Cytogenetically normal acute myeloid leukemia (CN- AML) belongs to standard-risk group, but molecular markers like NPM1 mutation and FLT3 mutation can change this to favourable or poor risk group. The aim of this study was quantitative assessment of minimal residual disease in CN-AML carrying NPM1 mutation A (NPM1A) with or without FLT3- ITD mutation. The study included 14 CN-AML patients (10F/4M), median age 52 years (range 34-72). Bone marrow aspirate at diagnosis and in follow up was used for molecular analysis. RQ-PCR was used to quantitate NPM1A (Ipsogen, France) while FLT3-ITD was detected by RT-PCR (Nakao et al, Leukemia 1996). Hematological parameters at diagnosis were as follows: leucocyte count median 29.0 x109/L (range 1.4-180.5), bone marrow blasts median 49% (range15-90), anemia and thrombocytopenia. Median follow up was 13 months (range 2-43). Mutated NPM1A normalized copy number (NCN) at diagnosis was 41882 (range 2736-131560), 6/14 patients were FLT3-ITD positive. After induction therapy all patients achieved hematological remission ; 8/14 patients remained NPM1A positive (NCN range 1-6370), among them 3 were at diagnosis FLT3-ITD negative patients, 3 patients who lost FLT3-ITD positive status and 2 patients who were still FLT3-ITD positive and relapsed after 2 months. Among 11 patients who were alive after consolidation therapy, 8 patients underwent and 2 patients were planned for stem cell transplantation. Among transplanted patients (median follow up 22 months, range 7-38), 5 are NPM1A negative while 2 patients who demonstrated considerable NPM1A positivity after induction and consolidation therapy still have detectable low NPM1A. In conclusion, although it is known that mutated NPM1 is not a parameter for risk stratification in FLT3 mutated CN-AML, quantitative measurement of mutated NPM1 is more reliable than detection of mutated FLT3 in molecular monitoring and follow up of patients as well as in relapse prediction.

Mutated NPM1; FLT3 mutation; cytogenetically normal AML; minimal residual disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2015.

objavljeno

Podaci o matičnoj publikaciji

Podaci o skupu

Leukemia&Lymphoma 2015., East and West: Linking Knowledge and Practice

poster

23.09.2015-27.09.2015

Dubrovnik, Hrvatska

Povezanost rada

Kliničke medicinske znanosti